Please provide your email address to receive an email when new articles are posted on . For the two-part UNIVERSE study, 12 children who underwent the Fontan procedure were enrolled in a single-arm ...

A multi-center study has identified critical risk factors that increase the likelihood of death in children with a heart defect who are awaiting or have recently undergone heart transplantation, ...

The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure. New data were announced from a phase 3 ...

Lupin has introduced Rivaroxaban for Oral Suspension in the US market, offering a generic version of Xarelto. This medication ...

It is also approved for thromboprophylaxis in children aged two years and above with congenital heart disease after the ...

CCHMC is building a new learning network to assess long-term complications of a procedure for people born with a variety of congenital heart defects. A doctor at Cincinnati Children’s Hospital Medical ...

Lupin announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States. Rivaroxaban for Oral Suspension, 1 mg/mL is bioequivalent to Xarelto for Oral Suspension, 1 mg/mL of ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...